Willem Pieter (@wpbrouwer) 's Twitter Profile
Willem Pieter

@wpbrouwer

Gastroenterology & Hepatology // MD & PhD // Research & Liver disease // CrossFit & Cycling

ID: 27002978

linkhttps://www.researchgate.net/profile/Willem_Pieter_Brouwer/ calendar_today27-03-2009 13:29:45

474 Tweet

101 Takipçi

142 Takip Edilen

Willem Pieter (@wpbrouwer) 's Twitter Profile Photo

CytoSorbents Highlights Survival Benefit of CytoSorb Therapy in Septic Shock - Sep 25, 2019 cytosorbents.mediaroom.com/2019-09-25-Cyt…

Willem Pieter (@wpbrouwer) 's Twitter Profile Photo

Check out our new publication which shows an improved long-term #survival for #septic #shock patients treated with #cytosorb CytoSorbents doi.org/10.1159/000512…

GI Pearls (@gi_pearls) 's Twitter Profile Photo

Episode 47 -January 2021 is out! Covering Malignant polyp recommendations, EOE in pregnancy, HE treatment, etc. #GITwitter #LiverTwitter #MedEd iTunes - cutt.ly/gipearls Spotify - cutt.ly/gipearls2 Stitcher - cutt.ly/gipearls3 Web -gipearls.com

Joost PH Drenth (@joostphdrenth) 's Twitter Profile Photo

Happy to share the news that our nationwide 🇳🇱paper on 'Aggressive fluid hydration to prevent post-ERCP pancreatitis (FLUYT): a multicentre, open-label, randomised controlled superiority trial' has been accepted by The Lancet Gastroenterology & Hepatology ❇️trial with 826 patients! United European Gastroenterology

Willem Pieter (@wpbrouwer) 's Twitter Profile Photo

Joining the #MAFLD debate: it’s not alcohol use that drives mortality risk in metabolic associated #fattyliver disease! doi.org/10.1002/hep.32… #livertwitter #alcohol #NAFLD #Hepatology HEPATOLOGY Journal

FattyLiverAlliance (@fattylivera) 's Twitter Profile Photo

Fib-4 is the most widely accepted and used NIT (non-invasive test) for MASLD and MASH initial assessments. In this video fireside chat, Willem Pieter shares the recent study presented at #easlcongress 2023: "METABOLIC DYSFUNCTION ASSOCIATED FIBROSIS-5 (MAF-5) SCORE ACCURATELY

EASL Education (@easledu) 's Twitter Profile Photo

#EASLStudio: 📢Anti-NASH drug expected in 2024 10%/25-30% of weight loss needed for effects on inflammation & fibrosis Semaglutide ➡️ useful as early treatment? Medications help to lose & maintain weight loss 👍Lifestyle change, combination therapy & multidisciplinary management

#EASLStudio:
📢Anti-NASH drug expected in 2024
10%/25-30% of weight loss needed for effects on inflammation & fibrosis
Semaglutide ➡️ useful as early treatment?
Medications help to lose & maintain weight loss
👍Lifestyle change, combination therapy & multidisciplinary management
Willem Pieter (@wpbrouwer) 's Twitter Profile Photo

Check out our new MAF-5 liver fibrosis risk score for the general population with metabolic dysfunction! This score outperforms existing scores such as FIB-4 and could be a game changer for clinical care pathways gastrojournal.org/article/S0016-… #Livertwitter American Gastroenterological Association (AGA) Gastroenterology

Check out our new MAF-5 liver fibrosis risk score for the general population with metabolic dysfunction!
This score outperforms existing scores such as FIB-4 and could be a game changer for clinical care pathways

gastrojournal.org/article/S0016-…

#Livertwitter <a href="/AmerGastroAssn/">American Gastroenterological Association (AGA)</a> <a href="/AGA_Gastro/">Gastroenterology</a>
HEPATOLOGY Journal (@hep_journal) 's Twitter Profile Photo

Original Article Comparison of diagnostic accuracy and utility of non-invasive tests for clinically significant liver disease in a general population with metabolic dysfunction Van Kleef et al. #LiverX tinyurl.com/245fzwhb

Original Article

Comparison of diagnostic accuracy and utility of non-invasive tests for clinically significant liver disease in a general population with metabolic dysfunction

Van Kleef et al. 
#LiverX
tinyurl.com/245fzwhb